Sanofi SA (NYSE:SNY) Short Interest Up 50.5% in March

Sanofi SA (NYSE:SNY) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 2,222,604 shares, a growth of 50.5% from the February 28th total of 1,476,668 shares. Based on an average trading volume of 1,407,869 shares, the short-interest ratio is presently 1.6 days. Approximately 0.1% of the shares of the stock are sold short.

SNY traded up $0.22 during midday trading on Friday, reaching $41.31. 1,575,659 shares of the company’s stock were exchanged, compared to its average volume of 997,073. The stock has a market cap of $103.61 billion, a price-to-earnings ratio of 13.20, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. Sanofi has a one year low of $37.43 and a one year high of $45.62.

Sanofi (NYSE:SNY) last posted its quarterly earnings data on Thursday, February 7th. The company reported $0.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.01. The company had revenue of $9 billion during the quarter, compared to analyst estimates of $9 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted $1.06 earnings per share. Equities research analysts expect that Sanofi will post 3.1 EPS for the current fiscal year.

The firm also recently disclosed an annual dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 8th will be paid a $1.7395 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a yield of 4.2%. Sanofi’s payout ratio is presently 38.34%.

A number of equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, February 28th. TheStreet downgraded shares of Sanofi from a “b” rating to a “c+” rating in a research report on Thursday, February 7th. Zacks Investment Research downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, January 14th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Sanofi has an average rating of “Hold” and a consensus price target of $51.00.

In other news, major shareholder Sanofi sold 131,115 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Sanofi by 10.0% during the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 22,467,022 shares of the company’s stock worth $975,294,000 after purchasing an additional 2,039,820 shares in the last quarter. Fisher Asset Management LLC lifted its position in Sanofi by 2.7% in the 4th quarter. Fisher Asset Management LLC now owns 16,041,052 shares of the company’s stock valued at $696,342,000 after acquiring an additional 414,369 shares in the last quarter. FMR LLC lifted its position in Sanofi by 6.2% in the 4th quarter. FMR LLC now owns 9,057,978 shares of the company’s stock valued at $393,207,000 after acquiring an additional 529,995 shares in the last quarter. Macquarie Group Ltd. lifted its position in Sanofi by 11.3% in the 3rd quarter. Macquarie Group Ltd. now owns 3,390,421 shares of the company’s stock valued at $151,450,000 after acquiring an additional 344,140 shares in the last quarter. Finally, Raymond James & Associates lifted its position in Sanofi by 12.1% in the 4th quarter. Raymond James & Associates now owns 774,746 shares of the company’s stock valued at $33,632,000 after acquiring an additional 83,399 shares in the last quarter. 7.04% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Sanofi SA (NYSE:SNY) Short Interest Up 50.5% in March” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/sanofi-sa-sny-short-interest-up-50-5-in-march.html.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: Trading Options- What is a Strangle?

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.